Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depot Formulation Clear all
Completed Phase 2 Interventional Results available

A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

NCT03953079
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Drug: GB-102, Aflibercept
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
50 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty

NCT00667446
View directory record Official record
Conditions
Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa), Tanner Staging, Depot Formulation, Suppression of LH, Central Precocious Puberty (CPP), Gonadotrophin-releasing Hormone (GnRH), Lupron, GnRH Analog, Pediatrics Central Precocious Puberty
Interventions
Leuprolide Acetate 3 Month Depot
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

NCT01710709
View directory record Official record
Conditions
Bipolar I
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
72
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 3 Interventional

Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer

NCT00128531
View directory record Official record
Conditions
Prostate Cancer
Interventions
leuprolide acetate
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
15
States / cities
Homewood, Alabama • Casa Granda, Arizona • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2007 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

NCT03695237
View directory record Official record
Conditions
Central Precocious Puberty (CPP)
Interventions
Leuprolide Acetate (LA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Long Beach, California • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Jul 21, 2026, 10:47 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients

NCT00630799
View directory record Official record
Conditions
Prostate Cancer
Interventions
leuprolide acetate
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
New Port Richey, Florida • Lawrenceville, New Jersey • Poughkeepsie, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00706654
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
39
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Study of Lupron Depot In The Treatment of Central Precocious Puberty

NCT00660010
View directory record Official record
Conditions
Puberty, Precocious
Interventions
Lupron (leuprolide acetate)
Drug
Lead sponsor
Abbott
Industry
Eligibility
Up to 10 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

NCT01567527
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Intramuscular (IM) Depot Aripiprazole, Intramuscular (IM) Depot Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00731549
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
96
States / cities
Chandler, Arizona • Anaheim, California • Cerritos, California + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

NCT01348100
View directory record Official record
Conditions
Schizophrenia
Interventions
Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00705783
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot, Placebo depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
43
States / cities
Chandler, Arizona • Anaheim, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

NCT01415960
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
San Diego, California • Daytona Beach, Florida • Ocala, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Not applicable Interventional

Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer

NCT00056654
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Leuprolide acetate
Drug
Lead sponsor
Abbott
Industry
Eligibility
Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
55
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion

NCT04085341
View directory record Official record
Conditions
Diabetic Macular Edema, Retina Vein Occlusion
Interventions
GB-102
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Phoenix, Arizona • Savannah, Georgia • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty

NCT00635817
View directory record Official record
Conditions
Puberty, Precocious
Interventions
Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg
Drug
Lead sponsor
Abbott
Industry
Eligibility
2 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

NCT01473953
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Healthy
Interventions
liraglutide-depot, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Results available

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

NCT01870999
View directory record Official record
Conditions
Schizophrenia
Interventions
aripiprazole IM depot, aripiprazole tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Cerritos, California • Garden Grove, California • Glendale, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Jul 21, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

NCT03249740
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
GB-102, Aflibercept
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Jul 21, 2026, 10:47 PM EDT